KA34

Calibr, a division of Scripps Research · Phase 1 active Small molecule

At a glance

Generic name	KA34
Also known as	KA-34
Sponsor	Calibr, a division of Scripps Research
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KA34 CI brief — competitive landscape report
KA34 updates RSS · CI watch RSS
Calibr, a division of Scripps Research portfolio CI